Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Armstrong Discusses Hereditary Prostate Cancer

November 1st 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer

November 1st 2017

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Dr. Berry on LHRH Antagonists Versus Agonists for Prostate Cancer

November 1st 2017

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Dr. Cooperberg on Ongoing Trials in Early Prostate Cancer

October 31st 2017

Matthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.

Dr. Armstrong Discusses AR-V7 Testing in Prostate Cancer

October 24th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer

October 20th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Dr. Berry on the Differences Between LHRH Antagonists and Agonists

October 19th 2017

William R. Berry, MD, medical oncologist, Duke University, talks about the differences between luteinizing hormone-releasing hormone (LHRH) antagonists and agonists.

Expert Discusses Improving MRI Testing for Prostate Cancer

October 18th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses improving MRI testing for patients with prostate cancer.

Dr. Hope on the Detection Sensitivity of PSMA-PET Scanning

October 17th 2017

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco, discusses the detection sensitivity of PSMA-PET scanning.

Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer

October 16th 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the existing marketing authorization for abiraterone acetate (Zytiga) in men with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer.

Advanced Prostate Cancer: Closing Thoughts

October 12th 2017

Promising Agents for the Treatment of Prostate Cancer

October 12th 2017

Optimizing Therapy with Radium-223 for Prostate Cancer

October 12th 2017

Prostate Cancer: Combination Therapy with Radium-223

October 12th 2017

Bone-Targeted Therapy for Prostate Cancer: Radium-223

October 12th 2017

mCRPC Therapy: Considerations in Therapy Selection

October 12th 2017

The Value of Therapeutic Layering in mCRPC

October 12th 2017

Hormone-Sensitive Prostate Cancer: Nuances in Therapy

October 12th 2017

Hormone-Sensitive PC: What is the Standard of Care?

October 12th 2017

Considering the Role of ADT in Advanced Prostate Cancer

October 12th 2017